Breye Therapeutics develops novel, orally administered ophthalmology drugs to meet the needs of patients suffering vision loss. The company addresses the unmet medical need for more effective therapies.

Breye Therapeutics

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Metric
Company Name	Breye Therapeutics	Ocular Therapeutix, Inc.
Symbol		OCUL
MSH ID	COM:BREYE	COM:OCUTX
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	DK	US
Stage
Employee Count		267
Website	breye.com	ocutx.com
LinkedIn		ocular-therapeutix-inc
Founders

Metric
Market Cap		1.11B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		58.44M
Revenue (LTM)
Revenue (NTM)
Gross Profit		53.16M
EBITDA		-79.40M
Operating Income		-82.38M
Net Income		-80.74M
EPS		-0.94
Diluted EPS		-0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.91
Operating Profit Margin		-1.41
EBITDA Margin		-1.36
Net Profit Margin		-1.49
Return on Equity		-0.63
Return on Assets		-0.21
Return on Capital Employed		-0.18

COM:BREYE

Breye Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-5.67
P/B Ratio		50.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		29.00
EV Multiple		-10.81

Metric
Days Sales Outstanding		149.52
Days Payables Outstanding		296.28
Days Inventory Outstanding		174.21
Operating Cycle		347.24
Cash Conversion Cycle		106.71
Asset Turnover		0.23

Metric
Operating Cash Flow		-70.23M
Free Cash Flow		-76.32M
Cash Flow to Debt		-0.85
Operating Cash Flow/Sales		-1.12
Free Cash Flow Yield		-0.13

Metric
Cash & Equivalents		195.96M
Accounts Receivable		-4.85M
Inventory		2.31M
Goodwill
Debt to Capitalization		0.46
Debt to Assets		0.51
Current Ratio		4.03
Quick Ratio		21.29

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.31
R&D to Revenue		1.01
SG&A to Revenue		0.60